- Generic Drug User Fee Amendments of 2012: questions and answers related to self-identification of facilities, review of generic drug submissions, and inspections and compliance1
- Generic Speech for Use in 1990-1991 [Reminiscence]1
- Generic drug development: stakeholders’ views of risk evaluation and mitigation strategies differ : report to the Chairman, Committee on Energy and Commerce, House of Representatives1
- Generic drug user fees: application review times declined, but FDA should develop a plan for administering its unobligated user fees : report to the Chairman, Committee on Health, Education, Labor, and Pensions, U.S. Senate1
- Generic drugs: FDA should make public its plans to issue and revise guidance on nonbiological complex drugs : report to Congressional requesters1
- Generic drugs: Stakeholder views on improving FDA’s information on patents : report to congressional committees1
- Genetic analysis of mammalian signaling pathways that activate STATs and NFkB1
- Genetically Modified Organisms1
- Genetics and privacy: a patchwork of protections1
- Geographic disparities affect access to buprenorphine services for opioid use disorder1
- Geographic expansion of Medicaid managed care organizations: assessing access to primary care in nonmetropolitan counties1
- Geography is destiny: differences in health care among Medicare beneficiaries in the United States and California1
- Georgia could better ensure that nursing homes comply with federal requirements for life safety, emergency preparedness, and infection control1
- Georgia: Latino children's health coverage facts1
- Georgia’s women of reproductive age face many barriers to health care1
- Geriatrician roles and the value of geriatrics in an evolving healthcare system1
- Germs go global: why emerging infectious diseases are a threat to America1
- Germs or embryos of four vertebrates1
- Gesund leben ist so einfach1
- Getting MAGI right: a primer on differences that apply to Medicaid and CHIP1